Ashish Chaturmohta Of Fortune Equity Brokers told CNBC-TV18, "Except for Ranbaxy Laboratories we are witnessing a very strong buildup in most of the stocks particularly Dr Reddys Laboratories. Cipla or even Aurobindo Pharma is one counter where we are seeing good recovery from lower levels. We have seen a buildup of almost 5 percent in Dr Reddys Laboratories and clearly when the market was correcting we have seen some amount of buying emerging in the stock."
''We are expecting a target of Rs 2,360 on the upside in Dr Reddys Laboratories in next one-two trading sessions. One can initiate a long position keeping Rs 2,250 as a stoploss," he adds. Also Read: Dr Reddys up 4%, CLSA rates 'outperform' on strong US bizDiscover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
